Literature DB >> 21376236

Activation of mTORC2 by association with the ribosome.

Vittoria Zinzalla1, Daniele Stracka, Wolfgang Oppliger, Michael N Hall.   

Abstract

The target of rapamycin (TOR) is a highly conserved protein kinase and a central controller of growth. Mammalian TOR complex 2 (mTORC2) regulates AGC kinase family members and is implicated in various disorders, including cancer and diabetes. Here, we investigated the upstream regulation of mTORC2. A genetic screen in yeast and subsequent studies in mammalian cells revealed that ribosomes, but not protein synthesis, are required for mTORC2 signaling. Active mTORC2 was physically associated with the ribosome, and insulin-stimulated PI3K signaling promoted mTORC2-ribosome binding, suggesting that ribosomes activate mTORC2 directly. Findings with melanoma and colon cancer cells suggest that mTORC2-ribosome association is important in oncogenic PI3K signaling. Thus, TORC2-ribosome interaction is a likely conserved mechanism of TORC2 activation that is physiologically relevant in both normal and cancer cells. As ribosome content determines growth capacity of a cell, this mechanism of TORC2 regulation ensures that TORC2 is active only in growing cells.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21376236     DOI: 10.1016/j.cell.2011.02.014

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  315 in total

1.  Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.

Authors:  Kazuhiro Tanaka; Ivan Babic; David Nathanson; David Akhavan; Deliang Guo; Beatrice Gini; Julie Dang; Shaojun Zhu; Huijun Yang; Jason De Jesus; Ali Nael Amzajerdi; Yinan Zhang; Christian C Dibble; Hancai Dan; Amanda Rinkenbaugh; William H Yong; Harry V Vinters; Joseph F Gera; Webster K Cavenee; Timothy F Cloughesy; Brendan D Manning; Albert S Baldwin; Paul S Mischel
Journal:  Cancer Discov       Date:  2011-09-13       Impact factor: 39.397

Review 2.  Regulation of TOR by small GTPases.

Authors:  Raúl V Durán; Michael N Hall
Journal:  EMBO Rep       Date:  2012-02-01       Impact factor: 8.807

Review 3.  Deconvoluting mTOR biology.

Authors:  Jason D Weber; David H Gutmann
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

4.  Aloe-emodin suppresses prostate cancer by targeting the mTOR complex 2.

Authors:  Kangdong Liu; Chanmi Park; Shengqing Li; Ki Won Lee; Haidan Liu; Long He; Nak Kyun Soung; Jong Seog Ahn; Ann M Bode; Ziming Dong; Bo Yeon Kim; Zigang Dong
Journal:  Carcinogenesis       Date:  2012-04-24       Impact factor: 4.944

Review 5.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

6.  Signaling in control of cell growth and metabolism.

Authors:  Patrick S Ward; Craig B Thompson
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-07-01       Impact factor: 10.005

Review 7.  Rapamycin-resistant effector T-cell therapy.

Authors:  Daniel H Fowler
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

8.  Dynamic changes in ribosome-associated proteome and phosphoproteome during deoxynivalenol-induced translation inhibition and ribotoxic stress.

Authors:  Xiao Pan; Douglas A Whitten; Curtis G Wilkerson; James J Pestka
Journal:  Toxicol Sci       Date:  2013-11-27       Impact factor: 4.849

9.  mTOR complex 2 phosphorylates IMP1 cotranslationally to promote IGF2 production and the proliferation of mouse embryonic fibroblasts.

Authors:  Ning Dai; Jan Christiansen; Finn C Nielsen; Joseph Avruch
Journal:  Genes Dev       Date:  2013-02-01       Impact factor: 11.361

10.  XPLN is an endogenous inhibitor of mTORC2.

Authors:  Nidhi Khanna; Yimin Fang; Mee-Sup Yoon; Jie Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.